Has Francis Pecoraro, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,783 in general payments to Francis Pecoraro, MD across 216 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Francis Pecoraro, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Francis Pecoraro, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Francis Pecoraro, MD

Interventional Pain Medicine · Wilmington, NCNPI 1528021086

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.9% of the total across 216 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Abbott accounts for 66.2% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $592 and has fallen 93.0% since, to $42 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in NC, where the typical reported total is $2,787.

$2,783in general payments, 2019–2025

Across 216 payments — averaging $12.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$2K
Collegium Pharmaceutical, Inc.$155
Ipsen Biopharmaceuticals, Inc$113
Daiichi Sankyo Inc.$108
AbbVie$77
Biodelivery Sciences International, Inc.$72
plus $416 from 13 others

What the payments were for

Food & beverage$2,67096%
Education$1134%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	148	$1,843
Collegium Pharmaceutical, Inc.	11	$155
Ipsen Biopharmaceuticals, Inc	2	$113
Daiichi Sankyo Inc.	16	$108
AbbVie(2 entities)	6	$77
Biodelivery Sciences International, Inc.	6	$72
Medtronic	4	$72
Pfizer	4	$63
Assertio Therapeutics, Inc.	4	$50
Redhill Biopharma Inc.	3	$49
Nevro Corp.	2	$30
Forte Bio-pharma LLC	2	$29
Amgen	2	$27
Valinor Pharma, LLC	1	$19
Boston Scientific	1	$18
Azurity Pharmaceuticals, Inc.	1	$18
Scilex Pharmaceuticals Inc.	1	$16
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$14
Arbor Pharmaceuticals, Inc.	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Proclaim Family of SCS IPGs$124

How this compares

$2,783 in reported general payments places this provider in the 45th percentile of 45 interventional pain medicine providers in North Carolina.

See all interventional pain medicine providers in North Carolina →

Medicare billing

Part B allowed, 2024

$683,064

Medicare patients

925

Services billed

21,596

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	67	$2,358
Morphine Sulfate ErMorphine Sulfate	14	$1,410
Oxycodone Hcl	86	$1,266
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	37	$1,005
Methadone Hcl	41	$827
Gabapentin	78	$612
Pregabalin	17	$291
Tramadol Hcl	32	$227
Tizanidine Hcl	32	$211
Baclofen	19	$197
Hydromorphone Hcl	18	$163
Meloxicam	43	$160
Cyclobenzaprine Hcl	25	$146
Lorazepam	98	$65
Trazodone Hcl	15	$33

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Wilmington

John KnabWilmington$9K
Sunil AroraWilmington$6K
Charles DanielsWilmington$2K
Timothy ChafinAhoskie$59K
Robert WilsonSalisbury$37K
John MansfieldAsheville$25K
Erin ChaneyJacksonville$22K
Kevin CostelloGreenville$22K
Scott JohnstonJacksonville$20K
Harsh GovilStatesville$19K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →